Advances in cardiovascular pharmacology.
This selective review of a few of the advances made in recent years indicates that we are entering a new era in cardiovascular pharmacology. Drugs with novel mechanisms of action, and modifications of existing drugs, are being developed in constantly increasing numbers. The clinical evaluation of these drugs will be an exciting but difficult challenge.
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000631:Aminopyridines / Q000494:pharmacology; D000676:Amrinone; D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002317:Cardiovascular Agents / Q000494:pharmacology*; D004298:Dopamine / Q000031:analogs & derivatives; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D020105:Milrinone; D009200:Myocardial Contraction / Q000187:drug effects; D011728:Pyridones / Q000494:pharmacology; D011968:Receptors, Histamine / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D000631:Aminopyridines; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D007093:Imidazoles; D011728:Pyridones; D011968:Receptors, Histamine; D014665:Vasodilator Agents; C029758:sulmazole; D020105:Milrinone; D000676:Amrinone; D004298:Dopamine